unstressed rats. Furthermore, CUMS induced a long-lasting increase in expression levels of the cation chloride cotransporter Na + -K + -Cl --Cl -(NKCC1) in the PVN but a transient decrease in expression levels of K + -Cl --Cl -in the PVN, which returned to the basal level 5 days after CUMS treatment. The NKCC1 inhibitor bumetanide decreased the basal firing activity of PVN-CRH neurons and normalized E GABA and the gabazine-induced excitatory effect on PVN-CRH neurons in CUMS rats. In addition, central administration of bumetanide decreased basal circulating CORT levels in CUMS rats. Conclusions: These data suggest that chronic stress impairs GABAergic inhibition, resulting in HPA axis hyperactivity through upregulation of NKCC1.
pathological disorders such as depression. Chronic stress is a critical environmental risk factor for depression, the etiology of which involves hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis [1] [2] [3] . However, the mechanisms underlying the hyperactivity of the HPA axis in chronic stress remain unknown. Corticotrophin-releasing hormone (CRH)-expressing neurons in the hypothalamic paraventricular nucleus (PVN) (PVN-CRH neurons) are an essential component of the HPA axis and critically regulate HPA axis activity and stress responses [3] . Despite the critical role of PVN-CRH neurons in the regulation of HPA axis activity, it has been difficult to functionally unravel the cellular mechanisms that regulate PVN-CRH neurons because they cannot be distinguished morphologically from other types of neurons. Visualizing CRH-expressing neurons by immunohistochemical analysis is difficult without prior administration of compounds that inhibit axonal transport to promote the somatic accumulation of neuropeptides [4] . In transgenic mice, PVN-CRH neurons can be tagged by specifically expressing green fluorescent protein driven by the endogenous Crh promoter [5] [6] [7] . However, many studies use established rat stress models to study HPA axis activity. Thus, we developed a novel genetic approach to reliably identify PVN-CRH neurons by expressing enhanced green fluorescent protein (eGFP) under the control of the rat Crh promoter. This allowed us to determine the alteration of biochemical and electrophysiological properties in eGFP-tagged CRH-expressing neurons in response to chronic stress.
CRH-expressing neurons receive both inhibitory GABAergic and excitatory noradrenergic and glutamatergic inputs [8] [9] [10] [11] . GABAergic synaptic inputs importantly regulate PVN-CRH neuron activity [12] . GABA A receptors are ligand-gated ion channels with a predominant permeability to Cl - [13, 14] . The GABA reversal potential (E GABA ) is a key determinant of the neuronal response to activation of GABA A receptors. When E GABA is lower than the cell resting membrane potential, GABA A receptor activation elicits a hyperpolarization of the cell membrane [15, 16] ; however, when E GABA is higher (as a result of high intracellular Cl -concentration), GABA A receptor activation results in depolarization of the cell membrane and enhanced neuronal excitability. The cation-chloride cotransporters, including Na + -K + -Cl --Cl -(NKCC1) and K + -Cl --Cl -(KCC2), play important roles in determining E GABA through regulation of the intracellular Cl -concentration [17, 18] .
It has been shown that E GABA is altered in several types of stress, including acute stress [19, 20] , chronic hyperosmotic stress [21] , and early life stress [22] , and in some neuronal disorders, including status epilepticus [23] , injury [24] , neuropathic pain [25] [26] [27] , cellular oxidative stress [28] , trauma [24, 29] , seizure [30] [31] [32] , and hypertension [33, 34] . However, the mechanism of GABA response in chronic unpredictable mild stress (CUMS) is not fully understood. It has been shown that both acute stress and chronic stress reduce GABA release in the PVN [35, 36] . Downregulation of KCC2 is responsible for the depolarizing shift of E GABA in various types of neurons in acute stress [19, 20] , status epilepticus [23] , injury [24] , neuropathic pain [25] [26] [27] , cellular oxidative stress [28] , trauma [24, 29] , and seizure [30] [31] [32] . In contrast, upregulation of NKCC1 was shown to be responsible for the depolarizing shift of E GABA in chronic hyperosmotic stress [21] and early life stress [22] . However, the aforementioned studies provide little information about the dynamic changes of NKCC1 and KCC2 in the post-stress period. In this study, we tested the hypothesis that a depolarizing shift in E GABA induced by upregulation of NKCC1 in PVN-CRH neurons contributes to the hyperactivity of the HPA axis in chronic stress. In addition, we determined the dynamic changes of these cation-chloride cotransporters in response to chronic stress.
Materials and Methods

Animals
This study was carried out by using male Sprague-Dawley rats (8-12 weeks old, Harlan, Indianapolis, Ind., USA). The rats were housed in standard conditions (22-24 ° C) with a 12-hour light/ dark cycle. The experimental protocols and surgical procedures were approved by the Animal Care and Use Committee of the University of Texas M.D. Anderson Cancer Center and conformed to the National Institutes of Health guidelines on the ethical use of animals.
CUMS Rat Model
The CUMS rat model provides a good analogy to the precipitation of depression by chronic, low-grade stressors in humans [37, 38] . The CUMS model was developed according to an established paradigm: male Sprague-Dawley rats were exposed to 2 stressors per day from a total of 8 stressors (cage rotation, cold isolation, light off, light on, forced swim, restraint stress, isolation housing, and food/water deprivation) for 11 days; stressors were randomly varied from day to day [39] [40] [41] . To avoid the influence of the final stressor in the CUMS paradigm, all measurements, including those of circulating corticosterone (CORT), sucrose preference test, and electrophysiological recordings, were performed 5-10 days after the CUMS treatment had been finished.
We measured serum CORT levels and performed a sucrose preference test [37, 38] to validate that the CUMS procedure was stressful. The serum was isolated from blood collected from the orbital sinus by high-speed centrifugation in serum collection 196 tubes (14,000 r.p.m., 5 min). CORT concentrations were measured by using an enzyme immunoassay and compared with a standard curve of known CORT concentration per the manufacturer's instructions (Enzo Life Sciences) [20] . To minimize variability, all samples from each experiment were stored at -80 ° C before testing in parallel. In addition, to determine whether prolonged CUMS treatment induces higher circulating CORT levels than does the 11-day CUMS treatment, another group of rats were exposed to CUMS for 20 days.
For the sucrose preference test, the rats were first trained to drink 0.7% sucrose solution for 48 h. Then, each rat was simultaneously exposed to 1 bottle containing 0.7% sucrose solution and 1 bottle containing tap water. The 2 bottles were randomly positioned (right/left), and positioning was counterbalanced across the rats. Because sucrose preference differs between the dark and light phases [42, 43] , we performed sucrose preference tests in both light-on (10.00-11.00 h) and -off (18.00-19.00 h) phases. The intake volumes of tap water or sucrose solution were determined in unstressed and CUMS groups by weighing the bottles. We summarized the intake volumes of tap water or sucrose solution in both light-on and light-off phases. The preference for sucrose was calculated as a percentage of consumed sucrose solution of the total amount of liquid intake. Sucrose preference was calculated as the amount of sucrose solution intake divided by total fluid intake (water intake + sucrose intake) ×100.
Identification of PVN-CRH Neurons
To efficiently identify CRH-expressing neurons in the rat PVN, we constructed a viral plasmid containing rat Crh promoter [44] and eGFP, and integrated this plasmid into an adenoassociated virus (AAV) vector construct. The full-length promoter fragment (-2,125/+94) was subcloned into the AAV vector expression cassette by using short regulatory elements (woodchuck postregulatory element 2 and short synthetic polyadenylation). The serotype of the AAV used was chimeric AAV1/2, which had AAV1 and AAV2 capsid proteins in a 1: 1 ratio. The chimeric AAV1/2 serotype has been widely used [45] . The packaging was performed by Genedetect Ltd. (Auckland, New Zealand). The viral vector construct contained the following components: inverted terminal repeat sequence from AAV2, rat Crh promoter, eGFP, woodchuck postregulatory element 2, and short synthetic polyadenylation. The titers of the packaged AAV-Crh promoter eGFP were 1 × 10 13 genome copies per ml. This viral construct was delivered into the rat PVN in vivo through microinjection (100 nl; stereotaxic coordinates: 1.8-2.1 mm caudal from the bregma, 0.5 mm lateral to the midline, and 7.3-7.6 mm deep from the surface of the cortex). After the injection, the muscle and skin were sutured, and the wound was closed. A 3-to 4-week period was allowed for the Crh promoter-driven eGFP to be specifically expressed in the PVN-CRH neurons. Then, under deep anesthesia, the rats were perfused transcardially, and the brain was removed. The hypothalamic slices containing eGFP-tagged neurons were immunostained with a specific antibody against CRH. Colocalization of eGFP and CRH immunoreactivity validated that eGFPtagged neurons expressed CRH. We then performed electrophysiological experiments in eGFP-tagged CRH-expressing neurons in hypothalamic slices. Because nonsecretory CRH-expressing neurons displayed a low threshold spike (LTS) whereas secretory CRH neurons did not, we first determined whether eGFP-tagged CRH displayed LTSs.
Intracerebroventricular and PVN Injections
For implanting an intracerebroventricular cannula, rats under isoflurane anesthesia were placed on a stereotaxic instrument (David Kopf Instruments, Tujunga, Calif., USA). A 26-gauge guide cannula extending 3.5 mm from the pedestal (Plastics One, Roanoke, Va., USA) was implanted through a 2-mm burr hole drilled in the skull 1.5 mm lateral to the midline and 1.0 mm caudal to the bregma. The guide cannula was affixed to the skull by using dental acrylic with 3 small machine screws. A dummy cannula extending 0.5 mm beyond the end of the guide cannula was then inserted, and a dust cap was placed over the external end of the dummy cannula. After surgery, buprenorphine (0.05 mg/kg) was injected subcutaneously for analgesia, and the rats were allowed to recover for 1 week. After a recovery period of a week, the dummy cannula was removed, and an injection cannula protruding 1.0 mm beyond the tip of the guide cannula was inserted into the guide cannula. Thus, the tip of the injection cannula targeted the lateral ventricle, which is 4.0-4.5 mm deep from the surface of the skull. The intracerebroventricular injections were performed through the injection cannula connected to a Hamilton syringe. Each injection consisted of a 10-μl solution delivered over 1 min. Bumetanide was dissolved in DMSO initially and then diluted in artificial cerebrospinal fluid (aCSF; the final concentration of DMSO was 0.5% v/v) at a concentration of 200 μ M [33] .
For the PVN injections, a bilateral guide cannula (26 gauge, 1.0 mm spacing between cannula, extending 7.0 mm from the pedestal; Plastics One) was implanted into the rat PVN. The tip of the guide cannula was positioned 1.0 mm dorsal to the intended drug injection site at the following coordinates (for PVN) according to Paxinos and Watson's atlas of the rat brain: 1.8 mm caudal and 0.5 mm lateral to the bregma and 8.0 mm ventral to the surface of the dura. As described for the guide cannula for intracerebroventricular injection, the bilateral guide cannula for PVN injection was affixed to the skull by using dental acrylic, a dummy cannula was inserted into each side of the guide cannula, and a dust cap was then placed over the external end of the dummy cannula. After a 1-week recovery period, the dummy cannula was removed, and a bilateral injection cannula with tips protruding 1.0 mm beyond the tip of the guide cannula was placed. Gabazine (135 pmol in 100 nl of aCSF) was dissolved in aCSF and injected bilaterally into the PVN [46, 47] . Fluorescent microspheres (0.04 μm, wavelength 580 nm) in the same volume as gabazine were delivered through the cannula at the end of the experiment to mark the infusion sites.
Electrophysiological Recordings in Brain Slices
Hypothalamic slices were prepared from the AAV-CRH-eGFP viral vector-injected rats. Briefly, the rats were decapitated under anesthesia with 2% isoflurane, and the brain was quickly removed and placed in ice-cold aCSF containing (in m M ) 124.0 NaCl, 3.0 KCl, 1.3 MgSO 4 , 2.4 CaCl 2 , 1.4 NaH 2 PO 4 , 10.0 glucose, and 26.0 NaHCO 3 (continually gassed with a mixture of 95% O 2 and 5% CO 2 ). A tissue block containing the PVN was trimmed and fixed with tissue glue on the stage of a vibrating microtome (VT1000, Leica Biosystems Inc., Buffalo Grove, Ill., USA). Coronal slices 300 μm thick were cut as described previously [48] [49] [50] . Then, the slices were transferred to an incubation chamber containing aCSF continuously gassed with a mixture of 95% O 2 and 5% CO 2 at 34 ° C for at least 1 h before the electrophysiological recordings.
The slices in the recording chamber were perfused (3 ml/min) with aCSF (gassed with 95% O 2 and 5% CO 2 ) at a temperature of Chronic Stress and NKCC1 Upregulation 197 34 ° C, which was maintained by using an in-line solution heater. We first identified eGFP-tagged neurons under an upright microscope (BX51WI; Olympus) equipped with epifluorescence illumination and differential interference contrast optics and performed cell-attached recordings in these neurons. The recording electrodes were pulled by using a micropipette puller (P-97; Sutter Instruments) from borosilicate capillaries (1.2 mm outer diameter, 0.68 mm inner diameter; World Precision Instruments). The resistance of the pipette was 3-6 MΩ when it was filled with an internal solution containing (in m M ) 140.0 K gluconate, 2.0 MgCl 2 , 0.1 CaCl 2 , 10.0 HEPES, 1.1 EGTA, 0.3 Na 2 -GTP, and 2.0 Na 2 -ATP, adjusted to pH 7.25 with 1 M KOH (270-290 mosm). To record spontaneous firing activity, cell-attached recording was performed in eGFP-tagged neurons at a holding current of 0 pA. Electrical signals were processed by using a Multiclamp 700B amplifier (Molecular Devices), filtered at 1-2 kHz and digitized at 20 kHz by using Digidata 1440 (Molecular Devices).
Cl --impermeable gramicidin-perforated recordings were performed [33, 51] through a glass pipette containing an internal solution containing (in m M ) 140 CsCl, 5 EGTA, and 10 HEPES, pH 7.4 adjusted with CsOH. Gramicidin was freshly dissolved in DMSO and then diluted into the pipette solution at a final concentration of 50 μg/ml. The tip of the recording pipette was backfilled with the internal pipette solution containing gramicidin. Also, the pipette solution contained a fluorescent dye, Lucifer yellow (0.5 mg/ml), to reveal whether the cell membrane was ruptured during recording. We determined E GABA in PVN-CRH neurons on the basis of GABA currents elicited by puff application of GABA (100 μ M ) at a series of holding potentials ranging from -90 to -30 mV at 10-mV increments. The duration of GABA puff application was 15 ms to prevent the induction of HCO 3 currents by GABA [52] . CGP55845 (2 μ M ) and tetrodotoxin (1 μ M ) were added to the bath solution to block GABA B receptors and action potential-dependent synaptic activity, respectively. The access resistances of the perforated recording were between 40 and 70 MΩ.
Neurosecretory PVN neurons regulate HPA axis activity, whereas nonneurosecretory PVN-CRH neurons regulate autonomic system activity and display LTSs [53] . To determine whether the eGFP-tagged neurons displayed LTSs, a series of depolarizing current pulses (30-45 pA, 400 ms) from a membrane potential of -95 mV was applied to the recorded neuron. The eGFP-tagged PVN neurons showing no LTS were used for the recording experiments described below.
Quantification of NKCC1 and KCC2 Protein Levels in the PVN
Both NKCC1 and KCC2 protein levels in the PVN were determined by Western blotting in unstressed and CUMS rats. After the hypothalamic slices had been sectioned, with the third ventricle used as a reference, the PVN tissue ( ∼ 0.5 mm in diameter) spanning from 1.08 to 2.12 mm caudal to the bregma was micropunched bilaterally under a dissection microscope. Total protein was extracted by using the bicinchoninic acid method (Thermo Scientific) according to the manufacturer's instructions. The extracted protein samples were run in 4-12% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Immobilon P, Millipore). The immunoblots were probed with a rabbit anti-NKCC1 (1: 500, Abcam), rabbit anti-KCC2 (1: 500, Abcam), and rabbit anti-GAPDH antibody (1: 1,000, ab37168, Abcam) for 24 h. On the second day, goat anti-rabbit horseradish peroxidase antibody (1: 5,000, Abcam) was applied to the immunoblots for 2 h at room temperature. An enhanced chemiluminescence kit (Life Sciences) was used to detect and enhance the protein bands, which were quantified by ImageJ software and normalized by the GAPDH optical density within the same samples.
Immunostaining for NKCC1 in PVN-CRH Neurons
To determine the distribution of NKCC1 in the PVN-CRH neurons, we performed double fluorescence labeling by using antibodies against CRH and NKCC1. To enhance CRH immunoreactivity in the PVN, rats were injected intracerebroventricularly with 50-60 mg of colchicine [4] . Rats were deeply anesthetized (with sodium pentobarbital 50 mg/kg by intraperitoneal injection) and rapidly perfused transcardially with 0.9% saline followed by 4% paraformaldehyde in 0.1 M phosphate-buffered saline (pH 7.4). The brains were removed and cut into 30-μm-thick frozen sections. After tissue sections had been treated with blocking agent, they were incubated with the primary antibody mixture (for NKCC1: rabbit anti-NKCC1 antibody, Alphadiagnostic International; for CRH: guinea pig anti-corticotrophin-releasing factor antibody, Peninsula Laboratories International, San Carlos, Calif., USA). The sections were incubated with a secondary antibody (for NKCC1: mouse anti-rabbit Alexa 488; for CRH: goat anti-guinea pig Alexa 594; Invitrogen, Carlsbad, Calif., USA). Confocal microscopy was used to visualize co-colocalization of the fluorescent markers.
Data Analysis
Data were presented as means ± SEM. The junction potential was corrected based on different potentials by using internal and external solutions. The E GABA was determined by using linear regression to calculate a best-fit line for the voltage dependence of GABA-induced currents. The intercept of the current-voltage line with the abscissa (on the voltage axis) was taken as the E GABA . For electrophysiological experiments, one neuron was recorded from one brain slice and at least 3 rats were included in each group. The Student t test was used to compare two data sets. For comparisons of more than two data sets, the repeated-measures ANOVA with Dunnett's post hoc test and two-way ANOVA with Bonferroni's post hoc test were performed to compare differences within and between groups, respectively. p < 0.05 was considered statistically significant.
Results
Identification of CRH-Expressing Neurons in the Hypothalamus
PVN-CRH neurons play a pivotal role in the regulation of the HPA axis and circulating CORT levels [54] . To reliably identify PVN-CRH neurons, we developed a novel AAV vector containing an eGFP gene under control of the rat CRH promoter ( fig. 1 A) . The AAV-CRH viral vector (1 × 10 13 titer, 100 nl) was injected into the PVN. To determine whether this viral vector changed HPA activity, we measured circulating CORT levels 3 weeks after the injection. In 7 rats, the pre-injection cir- culating CORT levels did not significantly differ from CORT levels 3 weeks after injection of the AAV-CRHeGFP vector (p > 0.05, fig. 1 B) , since the AAV-CRHeGFP vector did not change CORT levels. Thus, it was not necessary to test the effect of a control vector on circulating CORT levels. To validate that eGFP-tagged neurons were CRH-expressing neurons, we performed immunostaining by using specific antibody against CRH. The majority of eGFP-tagged (green) neurons (486 of 505 neurons, 96.2%) were CRH immunopositive (red, fig. 1 C) . By the use of a fluorescent microscope, we directly identified these eGFP-tagged neurons in brain slices ( fig. 1 D) . Thus, we were able to perform electrophysiological recordings of these eGFP-tagged neurons. Because nonneurosecretory PVN neurons generate LTSs whereas neurosecretory PVN neurons do not generate LTSs [53] , we performed the electrophysiological experiments described below in eGFP-tagged neurons not displaying LTSs ( fig. 1 E) . We found that GFP-tagged neurons included both nonneurosecretory (with LTS) and neurosecretory (without LTS) neurons. The presence or absence of LTS was verified at either the beginning or the end of the recording.
Chronic Stress Impairs GABAergic Inhibition in the PVN
Both 11-day and 20-day CUMS treatment significantly increased circulating CORT levels; the 11-day treatment (n = 8) increased levels from 13.1 ± 1.8 to 56.3 ± 3.1 ng/ml, and the 20-day treatment (n = 6) increased levels from 13.1 ± 1.8 to 59.7 ± 5.8 ng/ml (p < 0.05, fig. 2 A) . Because the post-treatment circulating CORT levels did not differ between 11-day and 20-day CUMS treatment (p > 0.05, fig. 2 A) , we used the 11-day CUMS treatment in the following experiments. Furthermore, sucrose preference was significantly decreased in the CUMS rats (n = 8) compared with that in 8 unstressed rats ( fig. 2 B) .
Since GABAergic inputs inhibit PVN neuroendocrine neurons to decrease circulating CORT levels [55] , blockade of GABA A receptors in the PVN elicits a robust increase in [19, 55] . We thus determined whether synaptic GABAergic inhibition in the PVN is impaired in CUMS rats. Because bicuculline can excite neurons through its effect on small-conductance Ca 2+ -activated K + channels in addition to blocking GABA A receptors [56] , we chose another GABA A receptor antagonist, gabazine [57] . Microinfusion of gabazine (135 pmol in 100 nl of aCSF) through the implanted cannula into the PVN elicited a robust increase in circulating CORT levels in unstressed rats ( fig. 2 C) . In contrast, gabazine infusion had no effect on circulating CORT levels in CUMS rats ( fig. 2 C) . The microinfusion sites marked by fluorescent microspheres (0.04 μm) in the PVN are shown in figure 2 D. This observation suggests that synaptic GABAergic inhibition in the PVN is markedly reduced in the chronic stress condition.
CUMS Impairs GABA Inhibition of PVN-CRH Neurons and Induces a Depolarizing Shift in E GABA
Because GABA A receptor-mediated inhibition is dependent on intracellular Cl -concentration, we assessed the alteration of GABAergic inhibition of eGFP-tagged PVN-CRH neurons by using cell-attached recording, which does not perturb intracellular Cl -. The basal firing rate of eGFP-tagged PVN-CRH neurons was significantly higher in CUMS rats (1.8 ± 0.1 Hz, n = 7 neurons) than in unstressed rats (1.3 ± 0.1 Hz, n = 9 neurons, p < 0.05, fig. 3 ). The PVN-CRH neurons displayed an irregular firing pattern without significant bursts, and this firing pattern of PVN-CRH neurons was not altered in CUMS rats. Bath application of the GABA A receptor antagonist gabazine (20 μ M ) [58, 59] significantly increased the firing rate of PVN-CRH neurons in unstressed rats (from 1.3 ± 0.1 to 2.0 ± 0.2 Hz, p < 0.05). In contrast, gabazine significantly decreased the firing rate in eGFP-tagged neurons in CUMS rats (from 1.8 ± 0.1 to 1.1 ± 0.1 Hz, p < 0.05, n = 9, fig. 3 A, B) . Next, we determined the effect of the GABA A receptor agonist muscimol on the firing activity of PVN-CRH neurons. Bath application of muscimol (10 μ M ) significantly decreased the firing rate of PVN-CRH neurons in unstressed rats (from 1.4 ± 0.1 to 0.5 ± 0.1 Hz, p < 0.05, n = 8 neurons) but significantly increased the firing rate of PVN-CRH neurons in CUMS rats (from 1.9 ± 0.1 to 3.0 fig. 3 C, D) . These observations suggest that GABA A -mediated inhibition switched to excitation in PVN-CRH neurons after CUMS. E GABA is a key determinant of the neuronal response to activation of GABA A receptors, and a depolarizing shift in E GABA leads to a switch from GABAergic inhibition to excitation in several pathological conditions [19, 33, 34] . Thus, we performed Cl --impermeable gramicidin-perforated recordings in eGFP-tagged PVN-CRH neurons in hypothalamic slices to measure the E GABA in unstressed and CUMS rats. The input resistances in eGFP-tagged neurons did not significantly differ between unstressed rats (1.3 ± 0.3 GΩ, n = 7 neurons) and CUMS rats (1.5 ± 0.4 GΩ, n = 8 neurons, p > 0.05). E GABA in eGFP-tagged PVN neurons from CUMS rats (n = 8 neurons) displayed a significant depolarizing shift (about 20 mV) compared with E GABA in eGFP-tagged PVN neurons from unstressed rats (n = 7 neurons, p < 0.05, fig. 4 A-C) . Bath application of the GABA A receptor antagonist gabazine (20 μ M ) completely blocked GABA-induced currents ( fig. 4 D) .
CUMS Induces a Long-Lasting Increase in NKCC1 Protein Levels and a Transient Reduction in KCC2 Levels in the PVN
The Cl -homeostasis of neurons in the central nervous system is primarily maintained by the Cl --importing transporter NKCC1 and Cl --extruding transporter KCC2 [18, 60, 61] . We determined the expression levels of NKCC1 and KCC2 by immunoblot analysis in PVN tissue obtained by the micropunch method in unstressed and CUMS rats. The 11-day CUMS treatment significantly increased NKCC1 protein band density by 94 ± 15% (n = 4 samples, p < 0.05) 3 days after completion of CUMS treatment and by 99 ± 25% (n = 4 samples, p < 0.05) 10 days after completion of CUMS treatment ( fig. 5 A, B) . We performed 2-hour restraint stress on unstressed rats in order to compare NKCC1 and KCC2 expression between acute stress and chronic stress. However, a 2-hour acute restraint stress did not significantly increase NKCC1 protein levels (100% vs. 123 ± 21%, n = 4 samples, p > 0.05, fig. 5 A) . In another two groups of rats, the 20-day CUMS treatment significantly increased NKCC1 protein levels in the PVN by 92 ± 16% (n = 4 samples, p < 0.05, fig. 5 E) , which did not differ significantly from the increase in NKCC1 levels induced by 11-day CUMS treatment (86 ± 18%, n = 4 samples). NKCC1 levels were measured 5 days after completion of CUMS treatment. We also determined the NKCC1 expression on CRH-expressing neurons by performing immunohistochemical staining with antibodies against CRH and NKCC1. NKCC1 immunoreactivities were extensive in PVN-CRH neurons ( fig. 5 F) . In addition, CUMS treatment significantly decreased the KCC2 protein level to 41 ± 9% (n = 4, p < 0.05) 3 days after completion of CUMS treatment. The KCC2 protein level returned to pre-CUMS levels within 5 days after completion of CUMS treatment ( fig. 5 C, D) . In another 6 rats, 2-hour restraint stress significantly decreased the KCC2 protein level to 42 ± 12% (p > 0.05).
Increased NKCC1 Activity Contributes to the Depolarizing Shift in E GABA and the Resultant GABAergic Excitation in PVN-CRH Neurons in CUMS Rats
It was previously reported that increased NKCC1 activity led to GABAergic excitation in neurons [33, 34, 62] . To determine whether upregulation of NKCC1 is in- volved in the switch from GABAergic inhibition to excitation, we assessed the effect of gabazine and muscimol on the firing activity of PVN-CRH neurons in brain slices treated with selective inhibitors of NKCC1. Incubating the brain slices with bumetanide (20 μ M for 2-4 h) at a concentration that selectively inhibits NKCC1 [63] not only reduced the basal firing rate, but also restored the stimulatory effects of gabazine on the firing activity of 8 PVN-CRH neurons from CUMS rats ( fig. 6 A, B) . Furthermore, bumetanide treatment restored the inhibitory effect of the GABA A receptor agonist muscimol against the firing activity of PVN-CRH neurons in CUMS rats ( fig. 6 C) . In addition, bumetanide treatment (20 μ M for 2-4 h) normalized the depolarizing shift in the E GABA of 
Inhibition of NKCC1 Activity Decreases Circulating CORT Levels in CUMS Rats
Since inhibition of NKCC1 activity decreased the basal neuronal activity of PVN-CRH neurons and restored GABAergic inhibition in the PVN in CUMS rats, we determined the effect of NKCC1 inhibitor on circulating CORT levels in CUMS rats. CUMS treatment significantly increased basal CORT levels. Because the high-concentration (200 μ M ) bumetanide solution that is required for microinjection became viscous, which makes it difficult to administer microinjections into the PVN via a glass pipette with a small tip, we administered bumetanide through an intracerebroventricular cannula. Intracerebroventricular administration of 200 μ M bumetanide (10 μl) did not alter circulating CORT levels in unstressed rats (n = 8) but significantly decreased CORT levels (from 56.8 ± 3.9 to 24.5 ± 1.4 ng/ml) 30 min after bumetanide administration in CUMS rats (n = 6, fig. 7 ). Within 2.5 h after intracerebroventricular bumetanide injection, circulating CORT levels returned to the pre-injection level in CUMS rats.
Discussion
This study indicates that CUMS impairs GABAergic inhibition of PVN-CRH neurons through upregulation of NKCC1 in the PVN. We found that CUMS caused HPA axis hyperactivity and a profound depolarizing shift in E GABA in PVN-CRH neurons. This depolarizing shift in E GABA was associated with increased NKCC1 protein levels in the PVN. Inhibition of NKCC1 activity decreased PVN-CRH neuron activity and HPA axis activity by reestablishing GABAergic inhibition in the PVN. These findings reveal a novel mechanism that is responsible for impaired GABAergic inhibition in CUMS.
Previous studies have shown that chronic stress alters GABAergic inhibition in the amygdala [64] , hippocampus [65] , and PVN [36] . For example, chronic unpredictable stress decreases presynaptic GABAergic synaptic inputs and postsynaptic GABA A receptor expression levels in PVN neurons [36] . We found in this study that disinhibition of PVN neurons with the GABA A receptor antagonist gabazine increased circulating CORT levels. However, in CUMS rats, administration of gabazine in the PVN failed to change circulating CORT levels. These data provide important in vivo evidence that the GABA Amediated inhibition of HPA axis activity and circulating CORT levels are markedly decreased under CUMS conditions. Since the PVN-CRH neurons are critical to the regulation of HPA axis activity and circulating CORT levels [3] , we speculate that GABA A -mediated inhibition of PVN-CRH neurons is altered after CUMS. To functionally assess the cellular mechanisms responsible for hyperactivity of PVN-CRH neurons, we identified these PVN-CRH neurons by specifically expressing eGFP under the control of a CRH promoter. Our immunocytochemical staining revealed that most eGFP-tagged neurons were CRH positive. Thus, this approach was able to distinguish PVN-CRH neurons in the rat brain. This unique method of identifying PVN-CRH neurons in the rat brain allowed us to assess neuronal function in our in vitro electrophysiological experiments.
Consistent with the increase in basal circulating CORT levels after CUMS, the basal firing activity of PVN-CRH neurons was significantly higher in CUMS rats than in unstressed rats. Strikingly, we found that GABA A receptor-mediated inhibition of PVN-CRH neurons switched to excitation in CUMS rats, as indicated by our finding that whereas gabazine increased the firing activity of PVN-CRH neurons in unstressed rats, gabazine induced an inhibitory effect on the firing activity of PVN-CRH neurons in CUMS rats. However, microinjection of gaba- zine into the PVN had no significant effect on circulating CORT levels in CUMS rats. The reasons for these inconsistent effects of gabazine on the activity of PVN-CRH neurons in brain slice preparations and on circulating CORT levels in vivo are not clear. A previous study showed that chronic unpredictable stress leads to an increase in excitatory glutamatergic inputs to the PVN-CRH neurons [66] . It is possible that under in vivo conditions, gabazine-induced inhibition of PVN-CRH neurons was offset by enhanced excitatory glutamatergic inputs, which were severed in in vitro brain slice preparations.
Chronic unpredictable stress reduces the synaptic GABA release in the PVN and decreases GABA A receptor expression [35, 36] . However, the switch from GABA Amediated inhibition to excitation observed in this study could not be explained by the reduction in GABA A receptors or GABA release. It has been shown that a switch from GABA inhibition to excitation results from a depolarizing shift in E GABA in several pathological conditions, including acute stress, early life stress, and chronic hyperosmotic stress [19, 21, 22] . We found that CUMS induced a depolarizing shift in E GABA in PVN-CRH neurons compared with E GABA in PVN-CRH neurons in unstressed rats. The depolarizing shift in E GABA represents an increase in intracellular Cl -concentration, which is determined by the cation-chloride cotransporters [17, 18] . Whereas KCC2 extrudes chloride, NKCC1 mediates chloride influx in neurons [17, 60] . Either KCC2 downregulation or NKCC1 upregulation leads to a depolarizing shift in E GABA and a resultant switch from GABAergic inhibition to excitation [15, 17, 19, 21] .
NKCC1 is expressed at a low level in the PVN in adult rats [67] . We found that the level of NKCC1 protein in the PVN was dynamically upregulated in response to CUMS treatment. It is not clear at what point NKCC1 protein levels in the PVN started to increase in response to CUMS. Our Western blot analysis revealed that NKCC1 protein levels were already increased 3 days after the completion of CUMS treatment. Furthermore, this increase in NKCC1 levels lasted for at least 10 days after the completion of CUMS treatment, whereas acute restraint stress had little effect on NKCC1 levels. We also found that both acute restraint stress and CUMS led to decreased KCC2 protein levels in the PVN. However, KCC2 protein levels returned to basal levels seen in unstressed rats 5 days after completion of CUMS treatment. Therefore, it is likely that the observed depolarizing shift of E GABA in the PVN-CRN neurons in CUMS was due to upregulation of NKCC1 but not to downregulation of KCC2. It seems that downregulation of KCC2 contributes to a depolarizing shift in E GABA observed in acute stress and the early phase (up to 5 days) of the post-CUMS period, whereas upregulation of NKCC1 is the predominant contributor to the depolarizing shift in E GABA in the late phase (after 5 days) of the post-CUMS period. It has been shown that chronic stress increases the response to new acute stressors [68] . The interaction between CUMS and 2-hour restraint stress deserves future studies. The hypothalamic PVN is heterogeneous, containing several types of neurons, including PVN-CRH neurons; thus, the upregulation of NKCC1 in PVN tissue may not be due solely to an increase in NKCC1 level in PVN-CRH neurons in CUMS rats. Our immunohistochemical staining confirmed that NKCC1 immunoreactivity was present in the PVN-CRH neurons.
Since upregulation of NKCC1 is critical to the switch from GABAergic inhibition to excitation and to the depolarizing shift in E GABA and in the PVN-CRH neurons, we conducted tests to determine whether inhibition of NKCC1 normalized the altered E GABA and restored the excitatory effect of gabazine on PVN-CRH neurons in CUMS rats. Treatment of brain slices with the NKCC1 inhibitor bumetanide not only reduced the basal firing activity of PVN-CRH neurons in CUMS rats, but also restored the excitatory effect of gabazine on the firing activity of PVN-CRH neurons in these rats. Furthermore, bumetanide treatment caused a hyperpolarizing shift in E GABA in PVN-CRH neurons after CUMS. These data indicate that NKCC1 upregulation is a key mechanism contributing to the depolarizing shift in E GABA and to the resultant inhibitory-to-excitatory switch in GABAergic control of PVN-CRH neurons in rats subjected to CUMS. It has been shown that acute exposure to a single stressor decreases KCC2 levels and results in a depolarizing shift in E GABA in the PVN neurons [19] . The current study further found that prolonged exposure to multiple stressors leads to a depolarizing shift in E GABA , which is due to an upregulation of NKCC1. Consistently, the important role of upregulation of NKCC1 in determining GABAergic excitation and the depolarizing shift of E GABA has been observed previously in chronic hyperosmotic stress and spontaneously hypertensive rats [21, 33] .
It has been shown that central administration of the NKCC1 inhibitor bumetanide reduces seizure progression [69] and sympathetic activity in neurogenic hypertension [33] . In this study, we found that inhibiting NKCC1 activity with bumetanide reduced circulating CORT levels in CUMS rats but did not change CORT levels in unstressed rats. Because the high-concentration bu-metanide solution that is required for microinjection became viscous, which makes it difficult to perform microinjection into the PVN via a glass pipette with a small tip, we administered bumetanide through an intracerebroventricular cannula to avoid injecting bumetanide directly into the PVN and thereby damaging PVN tissue. We realize that intracerebroventricularly infused bumetanide can reduce NKCC1 activity in other brain regions, including the dorsal medial hypothalamus and anterior hypothalamus. Thus, the decreased circulating CORT levels in CUMS rats treated with bumetanide may result from inhibiting NKCC1 activity in multiple brain regions. Since the hypothalamic PVN is the main brain region that controls HPA axis activity and circulating CORT levels, it is most likely that the PVN is the site mediating the effect of intracerebroventricular bumetanide on circulating CORT levels. However, we cannot completely rule out the possibility that other brain regions are involved in the reduction in circulating CORT levels following intracerebroventricular bumetanide infusion. The fact that NKCC1 upregulation induces a depolarizing shift in E GABA and contributes to the increased excitability of PVN-CRH neurons indicates that NKCC1 is a potential target for developing effective therapeutics to reduce responsiveness of the HPA axis to chronic stress.
